JPS6256898B2 - - Google Patents
Info
- Publication number
- JPS6256898B2 JPS6256898B2 JP55104362A JP10436280A JPS6256898B2 JP S6256898 B2 JPS6256898 B2 JP S6256898B2 JP 55104362 A JP55104362 A JP 55104362A JP 10436280 A JP10436280 A JP 10436280A JP S6256898 B2 JPS6256898 B2 JP S6256898B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- group
- carbon atoms
- represented
- main chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229920000642 polymer Polymers 0.000 claims description 28
- 125000004432 carbon atom Chemical group C* 0.000 claims description 22
- 125000000217 alkyl group Chemical group 0.000 claims description 19
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 238000006116 polymerization reaction Methods 0.000 claims description 10
- 125000002947 alkylene group Chemical group 0.000 claims description 9
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 7
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 239000000470 constituent Substances 0.000 claims description 5
- 125000006239 protecting group Chemical group 0.000 claims description 5
- -1 amine compound Chemical class 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003505 polymerization initiator Substances 0.000 claims description 3
- 101150009274 nhr-1 gene Proteins 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 description 16
- 239000012299 nitrogen atmosphere Substances 0.000 description 9
- 230000000259 anti-tumor effect Effects 0.000 description 8
- 229940041181 antineoplastic drug Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- BGGHCRNCRWQABU-JTQLQIEISA-N (2s)-2-amino-5-oxo-5-phenylmethoxypentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(=O)OCC1=CC=CC=C1 BGGHCRNCRWQABU-JTQLQIEISA-N 0.000 description 6
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- 108060003951 Immunoglobulin Proteins 0.000 description 6
- 102000018358 immunoglobulin Human genes 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 238000003756 stirring Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 231100000599 cytotoxic agent Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 239000002619 cytotoxin Substances 0.000 description 4
- 229920013730 reactive polymer Polymers 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- 229960003767 alanine Drugs 0.000 description 3
- 235000008206 alpha-amino acids Nutrition 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 229940072221 immunoglobulins Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RRHTVPZYUQSUFT-UHFFFAOYSA-N 2-(propyldisulfanyl)ethanamine Chemical compound CCCSSCCN RRHTVPZYUQSUFT-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000001371 alpha-amino acids Chemical class 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- OOTFVKOQINZBBF-UHFFFAOYSA-N cystamine Chemical compound CCSSCCN OOTFVKOQINZBBF-UHFFFAOYSA-N 0.000 description 2
- 229940099500 cystamine Drugs 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- ATCFYQUZTYQTJN-AXDSSHIGSA-N (2s)-2-amino-4-benzylpentanedioic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)CC1=CC=CC=C1 ATCFYQUZTYQTJN-AXDSSHIGSA-N 0.000 description 1
- UFULAYFCSOUIOV-XSCORUHJSA-N 2-aminoethanethiol Chemical group NCC[35SH] UFULAYFCSOUIOV-XSCORUHJSA-N 0.000 description 1
- MERLDGDYUMSLAY-UHFFFAOYSA-N 4-[(4-aminophenyl)disulfanyl]aniline Chemical compound C1=CC(N)=CC=C1SSC1=CC=C(N)C=C1 MERLDGDYUMSLAY-UHFFFAOYSA-N 0.000 description 1
- WCDSVWRUXWCYFN-UHFFFAOYSA-N 4-aminobenzenethiol Chemical group NC1=CC=C(S)C=C1 WCDSVWRUXWCYFN-UHFFFAOYSA-N 0.000 description 1
- CHNGAKGYDUCCBP-JTQLQIEISA-N C(C1=CC=CC=C1)OC([C@@H](N)CCS)=O Chemical group C(C1=CC=CC=C1)OC([C@@H](N)CCS)=O CHNGAKGYDUCCBP-JTQLQIEISA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- RXPFHUMNDYEGBN-VIFPVBQESA-N benzyl (2r)-2-amino-3-sulfanylpropanoate Chemical group SC[C@H](N)C(=O)OCC1=CC=CC=C1 RXPFHUMNDYEGBN-VIFPVBQESA-N 0.000 description 1
- 239000006229 carbon black Substances 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 229960005215 dichloroacetic acid Drugs 0.000 description 1
- HCUYBXPSSCRKRF-UHFFFAOYSA-N diphosgene Chemical compound ClC(=O)OC(Cl)(Cl)Cl HCUYBXPSSCRKRF-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 230000000512 lipotoxic effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000001226 reprecipitation Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Peptides Or Proteins (AREA)
- Polyamides (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
本発明は、側鎖に多数の保護されたカルボキシ
ル基を有すると共に、主鎖中又は主鎖のカルボキ
シル末端にジスルフイド結合含有基を有する重合
体及びその製造法に関する。そして、本発明の目
的とするところは、腫瘍細胞等の標的物に結合能
を有する抗腫瘍抗体等と、制ガン剤等の細胞毒物
を結合して標的指向型制ガン剤(抗腫瘍剤)等を
製造するに際し、両者を有効かつ効率良く結合さ
せるために用いられる重合体の製造中間体を提供
することにある。
従来、抗腫瘍抗体と細胞毒物を結合して標的指
向型制ガン剤を製造する際に、両者を効率良く結
合させるために反応性の重合体を媒介物として用
いることは公知である。
例えば、特開昭51−126281には、抗腫瘍免疫グ
ロブリンと、1分子当り制ガン剤を5〜500分子
共有結合しているポリマー担体、例えば、ポリダ
ルタミン酸をアミド結合によつて結合させて抗腫
瘍剤を得たことが開示されている。この方法で得
られた抗腫瘍剤は、腫瘍細胞と選択的に結合し、
腫瘍細胞に毒性を発揮することが期待されるもの
であり、非常に興味のある薬剤である。
しかしながら、この公知の抗腫瘍剤の欠点は抗
腫瘍抗体と毒性部(制ガン剤を結合したポリマー
担体)との結合がアミド結合によつて、即ち抗腫
瘍抗体中の遊離のアミノ基又はカルボキシル基を
介した結合によつて行なわれているという点であ
る。免疫グロブリンはその抗原認識部位にも多数
のアミノ基やカルボキシル基を有している。従つ
て、抗腫瘍免疫グロブリンに細胞毒物又は毒性部
をアミド結合によつて結合させる場合には、抗腫
瘍免疫グロブリンの抗原認識部位にも細胞毒物が
結合することになり、その結果、得られた抗腫瘍
剤は最早腫瘍細胞に対する結合能を全く失うか、
あるいは低下せしめられるという問題が生じるの
である。また、特開昭51−126281号記載の方法で
は、抗体分子内及びポリグルタミン酸の分子内、
あるいは同種分子間でもアミド結合が形成され
る。そしてこれらの望ましくないアミド結合の形
成の結果得られる抗腫瘍剤はその性能が低下し、
更に腫瘍の治療に用いるのが不適当な高分子量物
質を含むという問題も生じるのである。
本発明者らは、かかる先行技術の欠点を解決す
るために鋭意研究を行なつた結果、免疫グロブリ
ンの限られた位置に存在するジスルフイド結合を
利用して細胞毒物又は毒性部を結合させれば、前
記欠点のない抗腫瘍剤が得られることを見い出し
た。そして本発明は、かかる抗腫瘍剤あるいは又
その他の標的指向型薬剤を製造する際に最適に使
用できる反応性重合体を製造するための中間体を
提供するものである。
即ち、本発明は構成単位の60モル%以上が式
〔〕で表わされる構成単位からなり、
〔式〔〕において、Xはカルボキシル基の保護
基であり、炭素数1〜4のアルキル基、ベンジル
基を表わす。mは1〜4の整数を表わす。〕
主鎖中又は主鎖のカルボキシル末端に式〔〕
で表わされるジスルフイド結合含有基を有してい
る、
〔式〔〕において、Wは炭素数1〜4のアルキ
レン基を表わす。R1は水素原子又は炭素数1〜
4のアルキル基を表わす。R2は、式〔〕で表
わされる基が主鎖の末端基である場合には、アル
キル基、アラルキル基又はアリール基を表わし、
式〔〕で表わされる基が主鎖中に存在する場合
には、
The present invention relates to a polymer having a large number of protected carboxyl groups in its side chain and a disulfide bond-containing group in the main chain or at the carboxyl end of the main chain, and a method for producing the same. The purpose of the present invention is to manufacture target-directed anti-cancer drugs (anti-tumor drugs) by combining anti-tumor antibodies, etc. that have the ability to bind to targets such as tumor cells, and cytotoxic substances, such as anti-cancer drugs. The object of the present invention is to provide an intermediate for producing a polymer that can be used to effectively and efficiently combine the two. BACKGROUND ART Conventionally, it has been known to use a reactive polymer as a mediator in order to efficiently bind an antitumor antibody and a cytotoxin to produce a target-directed anticancer agent. For example, in JP-A No. 51-126281, an antitumor immunoglobulin and a polymer carrier having 5 to 500 anticancer drug molecules covalently bonded to each molecule, such as polydaltamic acid, are bonded through an amide bond to form an antitumor drug. It is disclosed that it has been obtained. The antitumor agent obtained by this method selectively binds to tumor cells,
It is a drug of great interest as it is expected to exert toxicity on tumor cells. However, a drawback of this known antitumor agent is that the antitumor antibody and the toxic moiety (polymer carrier bound to the antitumor agent) are bound to each other through an amide bond, that is, via a free amino group or carboxyl group in the antitumor antibody. The point is that this is done through a combination of Immunoglobulins also have many amino groups and carboxyl groups in their antigen recognition sites. Therefore, when a cytotoxic substance or toxic moiety is bound to an anti-tumor immunoglobulin through an amide bond, the cytotoxic substance will also bind to the antigen recognition site of the anti-tumor immunoglobulin, and as a result, the resulting Antitumor drugs no longer have the ability to bind to tumor cells at all, or
Otherwise, a problem arises in that it is lowered. In addition, in the method described in JP-A-51-126281, within the antibody molecule and within the polyglutamic acid molecule,
Alternatively, amide bonds are formed between molecules of the same type. And the antitumor agents obtained as a result of the formation of these undesirable amide bonds have reduced performance,
Furthermore, there is the problem that they contain high molecular weight substances that are unsuitable for use in tumor treatment. The present inventors have conducted extensive research to solve the drawbacks of the prior art, and have found that it is possible to bind cytotoxins or toxic moieties using disulfide bonds that exist in limited positions in immunoglobulins. It was discovered that an antitumor agent free from the above-mentioned drawbacks can be obtained. The present invention also provides intermediates for producing reactive polymers that can be optimally used in producing such antitumor agents or other target-directed drugs. That is, in the present invention, 60 mol% or more of the structural units consist of structural units represented by the formula [], In [Formula [], X is a protecting group for a carboxyl group, and represents an alkyl group having 1 to 4 carbon atoms or a benzyl group. m represents an integer from 1 to 4. ] Formula [] in the main chain or at the carboxyl terminal of the main chain
It has a disulfide bond-containing group represented by In [Formula [], W represents an alkylene group having 1 to 4 carbon atoms. R 1 is a hydrogen atom or has 1 or more carbon atoms
4 represents an alkyl group. When the group represented by the formula [] is the terminal group of the main chain, R 2 represents an alkyl group, an aralkyl group, or an aryl group,
When the group represented by the formula [] is present in the main chain,
【式】で表わされる2価の基であ
る。但し、W′はWと同一又は異なる炭素数1〜
4のアルキレン基であり、式〔〕のSと結合し
ている。R1′はR1と同一又は異なり、水素原子又
は炭素数1〜4のアルキル基を表わす。〕
重合度が5〜3000の分子中にジスルフイド結合
を有する重合体である。
本発明の重合体は、例えば、酸又はアルカリ分
解に付することによつて、側鎖に存在する多数の
保護カルボキシル基の保護基Xが離脱され、側鎖
に反応性の多数のカルボキシル基(又はその塩)
を有する反応性重合体に変換される。そして、こ
のカルボキシル基(又はその塩)を利用してこれ
に制ガン剤等の細胞毒物を結合することができ、
また主鎖中あるいは主鎖のカルボキシル末端に存
在するジスルフイド結合を利用してこれに抗腫瘍
抗体等の免疫グロブリンを結合することが出来る
ものである。
式〔〕において、Xはカルボキシル基の保護
基であり、炭素数1〜4のアルキル基、ベンジル
基、置換ベンジル基を表わすが、特にベンジル基
が好ましい。mは1〜4の整数を表わすが、好ま
しいのはmが1又は2の場合である。なお、本発
明の重合体中には、式〔〕で表わされる構成単
位のうち、例えば、m=1のものとm=2のもの
が混在していても良い。これらが合計で、全構成
単位のうちの60モル%以上、好ましくは80モル%
以上あればよいのである。
本発明の重合体中には、全構成単位の40モル%
未満の範囲で、式〔〕で表わされる構成単位以
外の構成単位が含まれていてもよい。これらの例
としては、例えば、α位側鎖にカルボキシル基
(又はその塩)を有しないグリシン、アラニン、
フエニルアラニン、セリン等のα−アミノ酸があ
る。
かかるα−アミノ酸からなる構成単位は、細胞
毒物との結合には何ら関与しないが、重合体の水
溶性や細胞毒物を結合して得られた重合体の脂溶
性や水溶性を調節するのに役立つ場合がある。従
つて、脂溶性や水溶性の調節が格別に必要ない場
合には、かかるα−アミノ酸からなる構成単位を
含有しないものの方が実用的に有利である。
式〔〕において、W及びW′は2価の有機基
を表わし、本発明の重合体を得る過程及びその後
の反応過程で何ら反応に関与しない不活性な基で
ある限り特に限定されない。これらの基として
は、例えば2−アミノエタンチオール残基(−
CH2CH2−)の如き直鎖の、あるいはシステイン
ベンジルエステル残基It is a divalent group represented by the formula: However, W′ has 1 to 1 carbon atoms, which is the same as or different from W.
4, and is bonded to S in formula []. R 1 ' is the same as or different from R 1 and represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. ] It is a polymer having a disulfide bond in the molecule with a degree of polymerization of 5 to 3000. For example, by subjecting the polymer of the present invention to acid or alkali decomposition, the protecting groups X of the many protected carboxyl groups present in the side chains are removed, and the many reactive carboxyl groups ( or its salt)
is converted into a reactive polymer with Then, using this carboxyl group (or its salt), a cytotoxic substance such as an anticancer drug can be bound to it,
Furthermore, immunoglobulins such as anti-tumor antibodies can be bound to this by utilizing disulfide bonds present in the main chain or at the carboxyl terminus of the main chain. In formula [], X is a protecting group for a carboxyl group, and represents an alkyl group having 1 to 4 carbon atoms, a benzyl group, or a substituted benzyl group, with a benzyl group being particularly preferred. m represents an integer of 1 to 4, preferably m is 1 or 2. In addition, in the polymer of the present invention, among the structural units represented by the formula [], for example, those in which m=1 and those in which m=2 may be mixed. The total amount of these is 60 mol% or more, preferably 80 mol% of the total structural units.
It is sufficient if there is more than that. In the polymer of the present invention, 40 mol% of the total structural units
Constituent units other than those represented by formula [] may be included within the range below. Examples of these include glycine, alanine, which does not have a carboxyl group (or its salt) in the α-position side chain,
There are α-amino acids such as phenylalanine and serine. Such a constituent unit consisting of α-amino acids does not participate in any way in binding with cytotoxins, but is useful in regulating the water solubility of the polymer and the fat solubility and water solubility of the polymer obtained by binding cytotoxins. It may be helpful. Therefore, if there is no particular need to adjust fat solubility or water solubility, it is practically advantageous to use a product that does not contain such a constituent unit consisting of an α-amino acid. In formula [], W and W' represent divalent organic groups, and are not particularly limited as long as they are inert groups that do not participate in any reaction during the process of obtaining the polymer of the present invention and the subsequent reaction process. These groups include, for example, 2-aminoethanethiol residue (-
linear or cysteine benzyl ester residues such as CH 2 CH 2 −)
【式】や
ホモシステインベンジルエステル残基
[Formula] and homocysteine benzyl ester residue
【式】の如き側鎖を有するアル
キレン基、4−アミノチオフエノール残基
Alkylene group having a side chain such as [Formula], 4-aminothiophenol residue
【式】の如き置換基を有しない、ある
いは置換基を有するフエニレン基が挙げられる
が、炭素数1〜4のアルキレン基が特に好まし
い。R1及びR1′は水素原子又は炭素数1〜4のア
ルキル基であるが、好ましいのは水素原子であ
る。R2は、式〔〕で表わされる基が主鎖の末
端基である場合には、アルキル基、アラルキル基
はアリール基である。この場合には、本発明の重
合体は下記の如く表わせる(但し、式〔〕の構
成単位が100モル%とする。)
(nは構成単位の数を表わす。)
R2は、式〔〕で表わされる基が主鎖中に存
在する場合には、Phenylene groups having no substituents or having substituents as shown in the formula are exemplified, and alkylene groups having 1 to 4 carbon atoms are particularly preferred. R 1 and R 1 ' are a hydrogen atom or an alkyl group having 1 to 4 carbon atoms, preferably a hydrogen atom. When the group represented by the formula [] is the terminal group of the main chain, R 2 is an alkyl group, and the aralkyl group is an aryl group. In this case, the polymer of the present invention can be expressed as shown below (however, the structural unit of formula [] is 100 mol%). (n represents the number of structural units.) When the group represented by the formula [] is present in the main chain, R2 is
【式】で表わされる2価
の基である。この場合には、本発明の重合体は下
記の如く表わせる(但し、式〔〕の構成単位が
100モル%とする)。
(p及びqは、それぞれ構成単位の数を表わす。)
本発明の重合体は、その重合度が5〜3000、好
ましくは10〜1500である。重合度が5未満の場合
には、本発明の重合体から得られた反応性重合体
に結合しうる細脂毒物の量が少ないので、抗腫瘍
剤等を製造する場合に効率の良い反応性の重合体
とならない。重合度が3000を越えると、その製造
が困難であるばかりでなく、抗腫瘍剤等を製造す
る場合に取扱いが不便となる。
本発明の重合体は、以下の如き方法で製造する
ことができる。
即ち、式〔〕
(x及びmの定義は式〔〕の場合と同じ。)
で表わされるN−カルボン酸無水物を、重合開始
剤として、式〔〕
R′2−S−S−W−NHR1 ……〔〕
〔W及びR1の定義は式〔〕の場合と同じ。R′2は
アルキル基、アラルキル基、アリール基又は−
W′−NHR′1で表わされる2価の基である。W′と
R′1の定義は式〔〕の場合と同じである。〕
で表わされる分子中にジスルフイド結合を有する
アミン化合物を用いて重合させる方法によつて製
造することができる。
式〔〕で表わされる重合開始剤としては、例
えば、シスタミン
(H2NCH2CH2SSCH2CH2NH2)、n−プロピル2
−アミノエチルジスルフイド
(CH3CH2CH2SSCH2CH2NH2)、4−アミノフエ
ニルジスルフイド
It is a divalent group represented by the formula: In this case, the polymer of the present invention can be expressed as follows (provided that the structural unit of formula [] is
100 mol%). (p and q each represent the number of structural units.) The polymer of the present invention has a degree of polymerization of 5 to 3000, preferably 10 to 1500. When the degree of polymerization is less than 5, the amount of lipotoxic substances that can bind to the reactive polymer obtained from the polymer of the present invention is small, resulting in efficient reactivity when producing antitumor agents, etc. It does not form a polymer. When the degree of polymerization exceeds 3000, it is not only difficult to produce, but also inconvenient to handle when producing antitumor agents. The polymer of the present invention can be produced by the following method. That is, the formula [] (The definitions of x and m are the same as in the case of the formula [].) Using the N-carboxylic acid anhydride represented by the formula as a polymerization initiator, the formula [] R' 2 -S-S-W-NHR 1 ...[ ] [Definitions of W and R 1 are the same as in formula []. R' 2 is an alkyl group, an aralkyl group, an aryl group, or -
It is a divalent group represented by W'-NHR' 1 . W′ and
The definition of R' 1 is the same as in the case of formula []. ] It can be produced by a method of polymerizing using an amine compound having a disulfide bond in the molecule represented by the following. Examples of the polymerization initiator represented by the formula [] include cystamine (H 2 NCH 2 CH 2 SSCH 2 CH 2 NH 2 ), n-propyl 2
-Aminoethyl disulfide (CH 3 CH 2 CH 2 SSCH 2 CH 2 NH 2 ), 4-aminophenyl disulfide
【式】シスチン
ジエステル類
([Formula] Cystine diesters (
【式】【formula】
無水テトラヒドロフラン120ml中に、γ−ベン
ジル−L−グルタミン酸10.0gを加へ分散液を調
製した。これとは別に窒素雰囲気下、クロロギ酸
トリクロロメチル20mlを、カーボンブラツク10.0
g上に徐々に70分かけて滴下しホスゲンを発生さ
せた。発生したホスゲンは、前記γ−ベンジル−
L−グルタミン酸の分散液に窒素雰囲気下で吸込
んだ。70分後に分散液は淡黄色透明液となつたの
で、ホスゲンを止め、その後窒素を1.5時間吸込
んで未反応のホスゲンを除去した。得られた透明
液から、窒素気流下減圧して溶媒を留去した
(140mmHg、27℃)。
残査に無水n−ヘキサン150mlを加えて溶解
し、その後氷浴上で5分間撹拌したところ白色固
体が析出した。この固体を窒素雰囲気下に酢酸エ
チル−n−ヘキサン(無水)の系で2回再沈澱に
より精製し、吸引ろ取後減圧乾燥してγ−ベンジ
ル−L−グルタメートN−カルボン酸無水物(下
記構造式を有する)
7.75gを白色固体として得た。このものの融点
は94.0〜94.5℃(分解)であり、収率は69.8%で
あつた。
実施例 1
参考例で得られたγ−ベンジル−L−グルタメ
ートN−カルボン酸無水物7.75gを乾燥1・4−
ジオキサン185mlに窒素雰囲気下、撹拌しながら
溶解した。かくして得られた溶液に、95mgのシス
タミン(H2NCH2CH2SSCH2CH2NH2)を10mlの乾
燥ジオキサンに溶解して得られた溶液を添加混合
し、窒素雰囲気下に室温で24時間撹拌して重合反
応を行なわせた。反応後、反応混合物を4のイ
ソプロピルエーテル中に撹拌しながら加え、生成
した重合体を沈澱させた。沈澱した白色の重合体
を取し減圧下に乾燥したところ、収量は6.19g
で収率は95.9%であつた。得られた重合体の平均
分子量を粘度法(ジクロル酢酸、25.0℃)で求め
たところ47300であつた。(P.Dotyら、J.Am.
Chem.Soc.、78巻、947頁、1956年参照)。
得られた重合体は、用いた原料と開始剤及び反
応機構から、下記式のポリ−γ−ベンジル−L−
グルタメートを主体とするものであることが合理
的に推定され、また赤外吸収スペクトルによつて
も確認された。
実施例 2
参考例で得られたγ−ベンジル−L−グルタメ
ートN−カルボン酸無水分物5.50gを乾燥1・4
−ジオキサン150mlに窒素雰囲気下、撹拌しなが
ら溶解した。かくして得られた溶液に、n−プロ
ピル2−アミノエチルジスルフイド
(CH2CH2CH2SSCH2CH2NH2)142mgを乾燥ジオ
キサン10mlに溶解して得られた溶液を加え、窒素
雰囲気下に室温で40時間撹拌して重合反応を行な
わせた。反応後、反応混合物を4のイソプロピ
ルエーテル中に撹拌しつつ加え、生成した重合体
を沈澱させた。沈澱を取し、減圧下に乾燥した
ところ、収量は4.41gで収率は96.3%であつた。
実施例 3
参考例で得られたγ−ベンジル−L−グルタメ
ートN−カルボン酸無水物10.0gとL−アラニン
N−カルボン酸無水物0.23gを、乾燥1・4−ジ
オキサン280mlに窒素雰囲気下に加え、撹拌して
溶解した。かくして得られた溶液に、198mgの4
−アミノフエニルジスルフイドを10mlの乾燥ジオ
キサンに溶解して得られた溶液を添加混合し、窒
素雰囲気下に室温で24時間撹拌して重合反応を行
なわせた。反応後反応混合物を4のイソプロピ
ルエーテル中に撹拌しつつ加え、生成した重合体
を沈澱物とした。重合体の沈澱を取し、減圧下
に乾燥し、8.21gを得た。収率は97%であつた。
得られた重合体は、用いた原料、開始剤、及び反
応機構から下記のγ−ベンジル−L−グルタメー
トとL−アラニンの共重合体であることが合理的
に推定され、又、赤外吸収スペクトルによつても
確認された。
A dispersion was prepared by adding 10.0 g of γ-benzyl-L-glutamic acid to 120 ml of anhydrous tetrahydrofuran. Separately, under a nitrogen atmosphere, add 20 ml of trichloromethyl chloroformate to carbon black 10.0
was gradually dropped over 70 minutes to generate phosgene. The generated phosgene is the γ-benzyl-
The dispersion of L-glutamic acid was sucked under a nitrogen atmosphere. After 70 minutes, the dispersion became a pale yellow transparent liquid, so the phosgene was stopped, and then nitrogen was sucked in for 1.5 hours to remove unreacted phosgene. The solvent was distilled off from the resulting transparent liquid under reduced pressure under a nitrogen stream (140 mmHg, 27°C). 150 ml of anhydrous n-hexane was added to the residue to dissolve it, and the mixture was stirred on an ice bath for 5 minutes to precipitate a white solid. This solid was purified by reprecipitation twice in a system of ethyl acetate-n-hexane (anhydrous) under a nitrogen atmosphere, collected by suction filtration, and dried under reduced pressure to produce γ-benzyl-L-glutamate N-carboxylic anhydride (described below). structural formula) Obtained 7.75 g as a white solid. The melting point of this product was 94.0-94.5°C (decomposition), and the yield was 69.8%. Example 1 7.75 g of γ-benzyl-L-glutamate N-carboxylic acid anhydride obtained in Reference Example was dried 1.4-
It was dissolved in 185 ml of dioxane under a nitrogen atmosphere with stirring. To the solution thus obtained, a solution obtained by dissolving 95 mg of cystamine (H 2 NCH 2 CH 2 SSCH 2 CH 2 NH 2 ) in 10 ml of dry dioxane was added and mixed, and the mixture was incubated at room temperature under nitrogen atmosphere for 24 hours. The mixture was stirred to carry out a polymerization reaction. After the reaction, the reaction mixture was added to the isopropyl ether of 4 with stirring to precipitate the produced polymer. When the precipitated white polymer was taken and dried under reduced pressure, the yield was 6.19g.
The yield was 95.9%. The average molecular weight of the obtained polymer was determined by the viscosity method (dichloroacetic acid, 25.0°C) and was found to be 47,300. (P. Doty et al., J. Am.
Chem.Soc., vol. 78, p. 947, 1956). The obtained polymer was determined from the raw materials, initiator, and reaction mechanism used to form a poly-γ-benzyl-L-
It was reasonably estimated that the substance was mainly composed of glutamate, and it was also confirmed by infrared absorption spectra. Example 2 5.50 g of γ-benzyl-L-glutamate N-carboxylic acid anhydride obtained in Reference Example was dried 1.4
-Dissolved in 150 ml of dioxane under nitrogen atmosphere with stirring. A solution obtained by dissolving 142 mg of n-propyl 2-aminoethyl disulfide (CH 2 CH 2 CH 2 SSCH 2 CH 2 NH 2 ) in 10 ml of dry dioxane was added to the solution obtained in this manner, and the mixture was stirred under a nitrogen atmosphere. The mixture was stirred at room temperature for 40 hours to carry out a polymerization reaction. After the reaction, the reaction mixture was added to the isopropyl ether of 4 with stirring to precipitate the produced polymer. When the precipitate was collected and dried under reduced pressure, the yield was 4.41 g, with a yield of 96.3%. Example 3 10.0 g of γ-benzyl-L-glutamate N-carboxylic acid anhydride obtained in Reference Example and 0.23 g of L-alanine N-carboxylic acid anhydride were added to 280 ml of dry 1,4-dioxane under a nitrogen atmosphere. and stirred to dissolve. To the solution thus obtained, 198 mg of 4
A solution obtained by dissolving -aminophenyl disulfide in 10 ml of dry dioxane was added and mixed, and the mixture was stirred at room temperature under a nitrogen atmosphere for 24 hours to carry out a polymerization reaction. After the reaction, the reaction mixture was added to the isopropyl ether in step 4 with stirring, and the resulting polymer was used as a precipitate. The polymer precipitate was collected and dried under reduced pressure to obtain 8.21 g. The yield was 97%.
The obtained polymer is reasonably estimated to be a copolymer of γ-benzyl-L-glutamate and L-alanine as described below from the raw materials, initiator, and reaction mechanism used, and also has an infrared absorption property. It was also confirmed by spectra.
Claims (1)
れる構成単位からなり、 〔式[]において、Xはカルボキシル基の保護
基であり、炭素数1〜4のアルキル基、ベンジル
基を表わす。mは1〜4の整数を表わす。〕 式[]の構成単位が100モル%でないとき、
残りの構成単位は、式[′] 〔式[′]において、Rは−H、−CH3、
【式】または−CH2OHで表わされる 基である。〕 で表わされる構成単位からなり、そして主鎖中又
は主鎖のカルボキシル末端に式[]で表わされ
るジスルフイド結合含有基を有している、 〔式[]において、Wは炭素数1〜4のアルキ
レン基を表わす。R1は水素原子又は炭素数1〜
4のアルキル基を表わす。R2は式[]で表わ
される基が主鎖の末端基である場合には、アルキ
ル基、アラルキル基又はアリール基を表わし、式
[]で表わされる基が主鎖中に存在する場合に
は、【式】で表わされる2価の基である。 但し、W′はWと同一又は異る炭素数1〜4のア
ルキレン基であり、式[]のSと結合してい
る。R1′はR1と同一又は異り、水素原子又は炭素
数1〜4のアルキル基を表わす。〕 重合度が5〜3000の分子中にジスルフイド結合
を有する重合体。 2 式[]においてXがベンジル基である、特
許請求の範囲第1項記載の分子中にジスルフイド
結合を有する重合体。 3 式[] 〔式[]において、Xはカルボキシル基の保護
基であり、炭素数1〜4のアルキル基、ベンジル
基を表わす。mは1〜4の整数を表わす。〕 で表わされるN−カルボン酸無水物、又はこの物
と式[′] 〔式[′]において、Rは−H、−CH3、
【式】または−CH2OHで表わされる 基である。〕 で表わされるN−カルボン酸無水物を、[]で
表わされるN−カルボン酸無水物の占める割合が
60モル%以上である範囲で混合したものを、重合
開始剤として、式[] R2′−S−S−W−NHR1 ……[] 〔式[]において、Wは炭素数1〜4のアルキ
レン基を表わす。R1は水素原子又は炭素数1〜
4のアルキル基を表わす。R2′はアルキル基、ア
ラルキル基、アリール基又は−W′−NHR1′で表
わされる基である。W′はWと同一又は異る炭素
数1〜4のアルキレン基であり、R1′はR1と同一
又は異り、水素原子又は炭素数1〜4のアルキル
基を表わす。〕 で表わされる分子中にジスルフイド結合を有する
アミン化合物を用いて重合させることを特徴とす
る、構成単位の60モル%以上が式[]で表わさ
れる構成単位からなり、 〔式[]において、X及びmの定義は前記式
[]の場合と同じ。〕 式[]の構成単位が100モル%でないとき、
残りの構成単位は、式[′] 〔式[′]において、Rの定義は前記式[′]
の場合と同じ。〕 で表わされる構成単位からなり、そして主鎖中又
は主鎖のカルボキシル末端に式[]で表わされ
るジスルフイド結合含有基を有している、 〔式[]において、Wは炭素数1〜4のアルキ
レン基を表わす。R1は水素原子又は炭素数1〜
4のアルキル基を表わす。R2は式[]で表わ
される基が主鎖の末端基である場合には、アルキ
ル基、アラルキル基又はアリール基を表わし、式
[]で表わされる基が主鎖中に存在する場合に
は、【式】で表わされる2価の基である。 但し、W′はWと同一又は異なる炭素数1〜4の
アルキレン基であり、式[]のSと結合してい
る。R1′はR1と同一又は異なり、水素原子又は炭
素数1〜4のアルキル基を表わす。〕 重合度が5〜3000の分子中にジスルフイド結合を
有する重合体の製造法。[Scope of Claims] 1 60 mol% or more of the structural units consist of structural units represented by the formula [], [In the formula [], X is a protecting group for a carboxyl group, and represents an alkyl group having 1 to 4 carbon atoms or a benzyl group. m represents an integer from 1 to 4. ] When the constituent units of formula [] are not 100 mol%,
The remaining structural units are expressed by the formula [′] [In formula ['], R is -H, -CH3 ,
It is a group represented by [Formula] or -CH 2 OH. ], and has a disulfide bond-containing group represented by the formula [] in the main chain or at the carboxyl terminal of the main chain, [In formula [], W represents an alkylene group having 1 to 4 carbon atoms. R 1 is a hydrogen atom or has 1 or more carbon atoms
4 represents an alkyl group. R 2 represents an alkyl group, an aralkyl group, or an aryl group when the group represented by formula [ ] is the terminal group of the main chain, and when the group represented by formula [] is present in the main chain, , is a divalent group represented by [Formula]. However, W' is an alkylene group having 1 to 4 carbon atoms, which is the same as or different from W, and is bonded to S in the formula []. R 1 ' is the same as or different from R 1 and represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. ] A polymer having a disulfide bond in the molecule with a degree of polymerization of 5 to 3000. 2. The polymer having a disulfide bond in the molecule according to claim 1, wherein in formula [], X is a benzyl group. 3 formula [] [In the formula [], X is a protecting group for a carboxyl group, and represents an alkyl group having 1 to 4 carbon atoms or a benzyl group. m represents an integer from 1 to 4. ] N-carboxylic acid anhydride represented by, or this product and the formula [′] [In formula ['], R is -H, -CH3 ,
It is a group represented by [Formula] or -CH 2 OH. ] The proportion of the N-carboxylic anhydride represented by [] to the N-carboxylic anhydride represented by [ ] is
A mixture in a range of 60 mol% or more is used as a polymerization initiator with the formula [] R 2 '-S-S-W-NHR 1 ...[] [In the formula [], W has 1 to 4 carbon atoms. represents an alkylene group. R 1 is a hydrogen atom or has 1 or more carbon atoms
4 represents an alkyl group. R2 ' is an alkyl group, an aralkyl group, an aryl group, or a group represented by -W'- NHR1 '. W' is the same or different from W and is an alkylene group having 1 to 4 carbon atoms, and R 1 ' is the same or different from R 1 and represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. ] Characterized by polymerization using an amine compound having a disulfide bond in the molecule represented by the formula, 60 mol% or more of the structural units are composed of the structural unit represented by the formula [], [In formula [], the definitions of X and m are the same as in the above formula []. ] When the constituent units of formula [] are not 100 mol%,
The remaining structural units are expressed by the formula [′] [In formula ['], the definition of R is the above formula [']
Same as in the case of ], and has a disulfide bond-containing group represented by the formula [] in the main chain or at the carboxyl terminal of the main chain, [In formula [], W represents an alkylene group having 1 to 4 carbon atoms. R 1 is a hydrogen atom or has 1 or more carbon atoms
4 represents an alkyl group. R 2 represents an alkyl group, an aralkyl group, or an aryl group when the group represented by formula [ ] is the terminal group of the main chain, and when the group represented by formula [] is present in the main chain, , is a divalent group represented by [Formula]. However, W' is an alkylene group having 1 to 4 carbon atoms, which is the same as or different from W, and is bonded to S in the formula [ ]. R 1 ' is the same as or different from R 1 and represents a hydrogen atom or an alkyl group having 1 to 4 carbon atoms. ] A method for producing a polymer having a disulfide bond in the molecule and having a degree of polymerization of 5 to 3000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10436280A JPS5730724A (en) | 1980-07-31 | 1980-07-31 | Polymer having disulfide bond in molecule and its preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10436280A JPS5730724A (en) | 1980-07-31 | 1980-07-31 | Polymer having disulfide bond in molecule and its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5730724A JPS5730724A (en) | 1982-02-19 |
| JPS6256898B2 true JPS6256898B2 (en) | 1987-11-27 |
Family
ID=14378712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10436280A Granted JPS5730724A (en) | 1980-07-31 | 1980-07-31 | Polymer having disulfide bond in molecule and its preparation |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5730724A (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS59159828A (en) * | 1983-03-02 | 1984-09-10 | Teijin Ltd | Reactive polymer and its production |
| JPS6071459A (en) * | 1983-09-27 | 1985-04-23 | Nichiro Kogyo Kk | Directional control method of fold printed matter |
| KR101207247B1 (en) | 2003-01-06 | 2012-12-03 | 넥타르 테라퓨틱스 | Thiol-selective water-soluble polymer derivatives |
-
1980
- 1980-07-31 JP JP10436280A patent/JPS5730724A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS5730724A (en) | 1982-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4410688A (en) | Macromolecular highly branched homogeneous compound | |
| Li et al. | Protein conjugation of thermoresponsive amine-reactive polymers prepared by RAFT | |
| ES2404685T3 (en) | Heterobifunctional poly (ethylene glycol) derivatives and methods for their preparation | |
| US4385169A (en) | Reactive alpha amino acid polymer | |
| JP4877225B2 (en) | Polyoxyalkylene derivatives | |
| US20060276618A1 (en) | Activated forms of water-soluble polymers | |
| RU95112841A (en) | Polymeric conjugate, method of its synthesis, derivative of 20-o-acylaminocamptothecine and method of its synthesis, pharmaceutical composition | |
| JPH09501674A (en) | Drug Delivery Drugs Incorporating Mitomycin | |
| Gkikas et al. | Well-defined homopolypeptides, copolypeptides, and hybrids of poly (L-proline) | |
| JP2005514505A (en) | Preparation and use of multi-arm dendritic and functional PEG | |
| US20090131589A1 (en) | Controlled molecular weight amino acid polymers having functionalizable backbones and end groups and processes for preparing the same | |
| US6677438B1 (en) | Method for attaching polyethylene glycol to macromolecules | |
| JPS6256898B2 (en) | ||
| JP2010531317A (en) | Method for preparing a hydrolyzable linker based on Fmoc | |
| JP3508234B2 (en) | Method for producing polyoxyalkylene derivative | |
| JP5286822B2 (en) | Process for producing polyamino acid or polyamino acid copolymer | |
| JP2593032B2 (en) | Heterofunctional polyethers at both ends, method for producing the polyethers and polymerization initiators | |
| JPS6238368B2 (en) | ||
| JPS6238369B2 (en) | ||
| Dessipri et al. | Trifluoroalanine N-carboxy anhydride: a reactive intermediate for the synthesis of low surface energy polypeptides | |
| Wang | Amino Acids: Insights and Roles in Heterocyclic Chemistry: Volume 3: N-Carboxyanhydrides, N-Thiocarboxyanhydrides, Sydnones, and Sydnonimines | |
| JPH0543560A (en) | New n-carboxyamino acid anhydride and production of polypeptide using the same as raw material | |
| US20210130408A1 (en) | Compound and method for producing the same | |
| JPS6219770B2 (en) | ||
| JPS5933292A (en) | Organogermanium compound |